

Biotechnology and Medical Care

68.4 ▼ 0.5 High 68.9 | Low 68.3 【+/-/X represent Up/Down/Not compared】

Company Information

Company Name	BIONIME CORPORATION
Spokesman	ROY HUANG
Website	www.bionime.com
Capital	NT 609,423,940
Main Business	<p>Bionime established in April 2003, BIONIME engages in the leading business of biotechnology and medical testing. Concerning medical testing, it can be further categorized into reagent and testing equipment. The product invested in and developed by BIONIME is a "blood glucose monitor and glucose strip," which combines the fields of reagent and medical equipment. Employing the advantages of the R&D & manufacturing of electronics in Taiwan and the exquisite design in Switzerland, BIONIME integrates expertise in biochemistry, medicine and electronics, to manufacture products with smart applications. At BIONIME , we are committed to developing bio-sensors. Indeed, we are dedicated to developing innovative BIO -sensors by applying Nanotechnology in the modification of either Injection Molding Electrodes or Insertion Modified Electrodes — the heart of BIONIME biosensors.</p>
Listing Date	2010/12/23
Industry	Biotechnology and Medical Care


Price and Trade Information



Date	Closing Price	Trade Volume	Date	Closing Price	Trade Volume	Date	Closing Price	Trade Volume
4/22	68.4	81,143	4/8	69.7	35,221	3/21	69.9	79,105
4/19	68.9	68,042	4/3	69.4	27,295	3/20	70.2	59,518
4/18	70.2	37,054	4/2	70.0	23,625	3/19	70.5	46,101
4/17	69.0	37,010	4/1	69.8	62,306	3/18	70.6	43,379
4/16	68.9	59,104	3/29	70.5	36,022	3/15	70.8	30,067
4/15	69.1	39,107	3/28	69.7	30,078	3/14	70.8	70,277
4/12	69.7	43,006	3/27	68.4	80,396	3/13	71.0	68,342
4/11	69.6	35,003	3/26	68.6	92,658	3/12	71.3	82,575
4/10	69.8	23,507	3/25	69.5	81,443	3/11	70.9	71,165
4/9	70.0	20,802	3/22	69.8	38,173	3/8	71.3	104,130

Historical Trading Information

Securities Investment Trust Companies



Foreign Investors



Dealers




Date	Securities Investment Trust Companies Difference(+)/(-)	Dealers Difference(+)/(-)	Foreign Investors Difference(+)/(-)	Date	Securities Investment Trust Companies Difference(+)/(-)	Dealers Difference(+)/(-)	Foreign Investors Difference(+)/(-)
4/22	0	+1,000	+22,000	3/28	0	0	-2,000
4/19	0	0	-5,000	3/27	0	0	-28,000
4/18	0	0	+4,000	3/26	0	0	-12,000
4/17	0	0	+6,000	3/25	0	+1,000	-16,000
4/16	0	0	-10,000	3/22	0	0	-13,000
4/15	0	0	-4,000	3/21	0	0	-20,000
4/12	0	0	-1,000	3/20	0	-1,000	-13,000
4/11	0	0	-8,000	3/19	0	0	-10,000
4/10	0	0	+2,000	3/18	0	0	-19,000
4/9	0	0	+2,000	3/15	0	0	-4,000
4/8	0	0	-5,000	3/14	0	0	+13,000
4/3	0	0	+4,000	3/13	0	-1	+3,000
4/2	0	0	-2,999	3/12	0	+1	+5,000
4/1	0	0	+3,000	3/11	0	0	-9,000
3/29	0	0	+4,000	3/8	0	0	-5,000

Purchase on Margin



Short Sale




Date	Purchase on Margin	Short Sale	Date	Purchase on Margin	Short Sale	Date	Purchase on Margin	Short Sale
4/22	-57	0	4/8	-5	0	3/21	+1	0
4/19	-11	0	4/3	+2	0	3/20	-7	0
4/18	-2	0	4/2	+1	0	3/19	-6	0
4/17	-6	0	4/1	-17	0	3/18	-5	0
4/16	-23	0	3/29	-1	0	3/15	+1	0
4/15	-5	0	3/28	+1	0	3/14	-5	0
4/12	-10	0	3/27	+5	0	3/13	-12	0
4/11	-8	0	3/26	-5	0	3/12	-16	0
4/10	+1	0	3/25	-2	0	3/11	+12	0
4/9	+2	0	3/22	0	0	3/8	+22	0

Company Financials

EPS




Income from continuing operations before tax



Quarter	Jan-Mar		Jan-Jun		Jan-Sep		Jan-Dec	
	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)	EPS	Income from continuing operations before tax (Thousand)
2023	-0.09	-15,565	0.08	7,566	-0.09	-5,478	0.10	-31,875
2022	0.23	7,954	0.88	54,831	1.05	64,997	1.50	86,483
2021	0.20	9,222	0.42	18,038	0.93	47,333	1.45	74,585
2020	-0.14	-11,068	-0.39	-29,750	0.29	-16,058	1.06	31,111
2019	0.12	6,836	0.79	54,408	0.89	64,961	1.85	134,567

Monthly Revenue



Monthly	Monthly Revenue	Monthly	Monthly Revenue	Monthly	Monthly Revenue	Monthly	Monthly Revenue	Monthly	Monthly Revenue
2024/03	177,098,000	2023/03	141,601,000	2022/03	259,364,000	2021/03	131,937,000	2020/03	107,680,000
2024/02	140,298,000	2023/02	150,250,000	2022/02	115,287,000	2021/02	121,064,000	2020/02	154,186,000
2024/01	151,078,000	2023/01	123,272,000	2022/01	100,995,000	2021/01	210,797,000	2020/01	91,540,000
2023/12	180,598,000	2022/12	186,148,000	2021/12	180,301,000	2020/12	290,319,000	2019/12	269,043,000
2023/11	132,608,000	2022/11	183,793,000	2021/11	150,125,000	2020/11	117,448,000	2019/11	170,764,000
2023/10	176,451,000	2022/10	226,694,000	2021/10	147,234,000	2020/10	99,385,000	2019/10	311,630,000
2023/09	128,176,000	2022/09	255,740,000	2021/09	185,323,000	2020/09	199,098,000	2019/09	159,536,000
2023/08	121,393,000	2022/08	144,384,000	2021/08	148,344,000	2020/08	151,697,000	2019/08	141,004,000
2023/07	175,574,000	2022/07	164,715,000	2021/07	162,210,000	2020/07	117,052,000	2019/07	185,973,000
2023/06	182,675,000	2022/06	259,327,000	2021/06	155,828,000	2020/06	122,062,000	2019/06	156,389,000
2023/05	154,875,000	2022/05	138,974,000	2021/05	126,419,000	2020/05	119,822,000	2019/05	216,116,000
2023/04	88,096,000	2022/04	175,027,000	2021/04	130,341,000	2020/04	117,527,000	2019/04	198,277,000

PE ratio



Date	PE ratio	Date	PE ratio	Date	PE ratio
4/22	684.00	4/8	697.00	3/21	699.00
4/19	689.00	4/3	694.00	3/20	702.00
4/18	702.00	4/2	700.00	3/19	705.00
4/17	690.00	4/1	698.00	3/18	706.00
4/16	689.00	3/29	705.00	3/15	708.00
4/15	691.00	3/28	697.00	3/14	191.35
4/12	697.00	3/27	684.00	3/13	191.89
4/11	696.00	3/26	686.00	3/12	192.70
4/10	698.00	3/25	695.00	3/11	191.62
4/9	700.00	3/22	698.00	3/8	192.70

Announcements

(Please refer to [mops](#) for the most updated information)

Subject	Date
▶ The Company's Board of Directors resolved to convene the 2024 Annual General Shareholders Meeting	2024/03/14 18:09:58
▶ Resolution by the board of directors to distribute dividends.	2024/03/14 18:10:18
▶ The Company's 2023 consolidated financial statements have been approved by the Board of Directors.	2024/03/14 18:10:50
▶ Announcement of changes in acting spokesperson, financial officer, and corporate governance officer.	2024/01/23 19:00:12
▶ Approval of Capital Expenditure for CGM (Continuous Glucose Monitoring System) by the Board of Directors	2024/01/23 19:00:30

Corporate Action

Year	Shareholders' meeting date	Period	Cash dividends	Stock dividends
2023	-	2023	0.09500	0.00000
2022	-	2022	0.38000	0.00000
2021	-	2021	1.25000	0.00000
2020	-	2020	0.85589	0.00000
2019	-	2019	1.51000	0.00000